February 2026 Research Update

This month added real-world evidence that RNA-silencing treatments can achieve strong lowering of transthyretin (the protein that forms amyloid) in people with ATTRv, including many with heart involvement. Across studies, the lab signal (lower blood transthyretin) moved in a consistent direction, while short-term symptom and heart measures were more about stability than clear improvement. This helps separate what looks reliable right now (protein lowering) from what still needs longer follow-up (day-to-day and heart outcomes). [1] [2] [3]

In a UK single-center crossover analysis of 112 patients who received patisiran and then switched to vutrisiran, most people had lower blood transthyretin levels after the switch, and the first follow-up blood test happened sooner on vutrisiran. The study did not report whether symptoms or function changed with the switch, so the main information here is about differences in transthyretin suppression in routine care. [1]

In a small 6-month prospective study of 25 people starting vutrisiran, quality-of-life and nerve-impairment scores did not change in a statistically clear way, but results were described as maintained or slightly improved. Blood transthyretin levels were maintained or reduced to undetectable levels in all patients, and no treatment-related adverse events were reported in this cohort. This provides a short-term snapshot of what monitoring can look like in everyday practice, but it cannot answer longer-term questions. [2]

A French multicenter retrospective study focused on ATTRv patients with cardiomyopathy who either switched from tafamidis to RNA-silencing therapy (patisiran or vutrisiran) or added RNA-silencing therapy to tafamidis. During the tafamidis-only period, about 1 in 4 were reported to worsen, while after switching or adding RNA-silencing therapy, most were reported stable and none were reported to worsen, with a small group improving. Many patients switched because of neurologic progression, so these results reflect mixed nerve-and-heart disease situations rather than heart-only care. [3]

For patients and caregivers, this month most strongly reinforces a practical point about monitoring: in real-world settings, RNA-silencing therapies are consistently linked with large drops in blood transthyretin, which is a direct measure of the target they are designed to suppress. What remains less settled from these studies is how much symptom relief or heart improvement to expect in the short term, because the available follow-up was limited and some results emphasized stability rather than clear change. These findings may matter now as context for understanding lab results seen during treatment and why different therapies might be compared by how much they suppress transthyretin, but they do not by themselves prove which approach leads to better long-term outcomes. [1] [2] [3]

This month clarified how much a persons disease pattern before liver transplantation relates to what happens years later. In a large international registry, survival after transplant was measured in decades for many patients, but outcomes differed across groups, especially for those with heart involvement before transplant. The same dataset also highlighted that nerve-related symptoms do not all change at the same pace after transplant, with autonomic problems tending to worsen earlier. [4]

Using the Familial Amyloidotic Polyneuropathy World Transplant Registry, researchers followed 1762 transplanted ATTRv patients and reported a 25-year survival of 32.4% and a median survival of 20.4 years. People categorized as having a cardiac phenotype before transplant had shorter median survival (15.2 years) than groups without that cardiac classification. Older age and longer disease duration at transplant were linked with higher mortality, while higher modified body mass index (a nutrition-related measure) was linked with lower mortality. [4]

The registry analysis also described post-transplant progression patterns, not just survival. Autonomic neuropathy (problems like blood pressure, bowel, bladder, or heart-rate regulation) was reported to deteriorate earlier than peripheral neuropathy or other non-nerve symptoms after transplant. This helps explain why some people may notice certain symptom areas changing even after a treatment that reduces mutant transthyretin production from the liver. [4]

For patients and caregivers, this registry study mainly adds perspective for long-term planning and expectations rather than offering a new treatment option. It helps clarify that, among people who did receive liver transplantation, heart involvement before transplant was one of the markers linked with shorter survival, and autonomic symptoms could worsen earlier than other parts of neuropathy after transplant. What remains uncertain is how well these historical outcomes (transplants up to 2012) apply to people diagnosed and treated in more recent years, because the registry spans decades with variable reporting and evolving care. [4]

This month, several studies focused on measurement: how to detect ATTRv accurately and how to follow changes over time. The clearest message was that results can depend strongly on the tool or data source used, and standardization matters. Together, these studies explain why two tests (or two hospitals) may not always agree, even when they are looking for the same underlying disease. [5] [6] [7] [8]

For tracking nerve damage, a prospective cohort following 48 ATTRv participants reported that a blood marker called neurofilament light chain (NfL, a signal of nerve injury) separated symptomatic from asymptomatic carriers when converted into an age- and BMI-adjusted score. In a small number of people who transitioned from carrier to symptomatic disease, NfL rose before symptoms, and NfL levels decreased after gene-silencing therapy (patisiran or vutrisiran). In the same cohort, another marker (GFAP) did not reliably match disease status or progression. [6]

A separate study addressed a practical problem: different lab platforms can give different NfL numbers even on the same samples. In 73 ATTRv variant carriers and 165 healthy controls, three NfL immunoassays showed good correlation but systematic differences in absolute values, and the authors reported that using Z-scores could make results more comparable across platforms. The study also cautioned that one platform tended to overestimate low NfL levels, which matters most when values are near the low end of detection. [5]

For detecting heart amyloid in variants where bone scintigraphy can be less sensitive, a small prospective case series reported that [11C]PiB PET/CT showed cardiac uptake in most hereditary ATTRv patients whose bone scans were negative. In contrast, the few patients with positive bone scintigraphy had negative or inconclusive PiB results, consistent with the idea that different fibril types bind differently to these tracers. Brain PET findings were mixed and did not consistently match suspected brain involvement, so that part remains uncertain. [7]

For research that uses hospital registries, a Danish validation study found that amyloidosis diagnosis codes were usually correct for amyloidosis overall, but ATTRv subtype coding was less reliable than ATTRwt or AL. ATTRv positive predictive value was 57%, and the authors noted that incomplete genetic testing could contribute to confusion between ATTRwt and ATTRv in routine records. This matters because registry-based studies can look more precise than they really are if subtypes are not well captured. [8]

For patients, these studies mainly help explain why monitoring and diagnosis can feel complicated, and why numbers may not match across centers. Standardizing NfL results and using NfL to distinguish symptomatic from asymptomatic carriers may matter in the future if adopted more widely, especially for following neuropathy over time and interpreting response signals after gene-silencing therapy. PiB PET/CT may also matter later for people with specific ATTRv variants where bone scans can miss heart involvement, but evidence is still early because the study was very small and did not settle how best to interpret brain findings. The registry validation study matters now mostly as a reminder that large database studies can misclassify ATTRv unless genetic testing is consistently captured, which affects how confidently patients can interpret headlines based on registry data. [6] [5] [7] [8]

This month included early-stage evidence at two ends of the spectrum: one individual case that highlights real diagnostic confusion, and one laboratory study that explains what amyloid looks like at the molecular level. Together, they reinforce that ATTRv is diverse and that test results can be misleading in unusual variants. They also suggest there may be shared structural features across different ATTR forms that could support future diagnostic approaches, although this is not yet a clinical tool. [9] [10]

In a single case, a 52-year-old woman with cardiac and autonomic neuropathy had initial testing that pointed toward AL amyloidosis, but genetic testing later confirmed a homozygous ATTRv variant (p.Ala101Val). The report noted negative bone scintigraphy and inconclusive tissue typing, showing how ATTRv can be missed or mis-typed when standard tests are not definitive. The patient was treated with tafamidis and the authors reported stabilization with some improvement in neurologic symptoms. [9]

In a structural biology study using cryo-electron microscopy on cardiac amyloid fibrils taken from three people with neuropathy-associated ATTR variants (P24S, A25S, D38A), the fibrils shared a common amyloid core with wild-type ATTR and most cardiac ATTRv. In plain language, despite different gene changes and different clinical pictures, the deposited amyloid in the heart looked similar in a key way. This is laboratory research, so it does not predict a persons outcome, but it helps explain why a single diagnostic approach might work across multiple ATTR types if it targets shared structure. [10]

For patients and caregivers, the case report matters as a real example that ATTRv can sometimes look like a different amyloidosis type on early testing, and that genetic testing can be decisive when other results are unclear. The cryo-EM study is mainly background science for now, but it helps clarify that different ATTR variants may still form very similar amyloid structures in the heart, which could support future diagnostic tests. What remains uncertain is how these structural findings translate into practical, widely available testing, because the study examined only 3 samples and did not evaluate patient outcomes. [9] [10]